(budesonide/formoterol fumarate dihydrate)
Patients have been known to express a preference for a specific inhaler device. This can make it easier to teach inhaler technique as well as increasing the likelihood of correct use while decreasing the chance of non-compliance.2
Poor inhaler technique can lead to poor control of asthma and COPD. It may result in reduced lung deposition,3 increased symptoms and exacerbations,4,5 potentially leading to emergency hospital admissions.
DuoResp Spiromax® has an award-winning design6 with the effective combination of drugs you know.
DuoResp Spiromax® is ready in one flip of a cover with consistent dose delivery in real-word conditions7 and dose confirmation. It works across inspiratory flow rates (~30-90 L/min).7,8
In addition to the healthcare professional and patient benefits, DuoResp Spiromax® could potentially provide annual savings of £40.8 million to the NHS.9
DuoResp Spiromax® is indicated in adults 18 years of age and older only.1
DuoResp Spiromax® is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
Chronic Obstructive Pulmonary Disease
Symptomatic treatment of patients with severe COPD (FEV1 < 70% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1
Teva Pharma B.V.
Marketing Authorisation number(s)
Let's Talk Respiratory is our educational programme of supportive materials, resources and some of the latest news in respiratory for both you and your patients. Our aim is to support you and encourage you, help empower patients and to make a real difference to the lives of those living with asthma and COPD.
1. DuoResp Spiromax® 320 micrograms/9 micrograms and 160 micrograms/4.5 micrograms inhalation powder - Summary of Product Characteristics
2 Price D et al. Resp Med 2013; 107:37-46
3 Giraud V, Roche N. Eur Resp J 2002; 19:246-251
4 Melani AS et al. Resp Med 2011; 105:930-938
5 Kemp L et al. Clinicoecon Outcomes Res 2010; 2:75-85
6 http://www.devicelink.com/expo/awards/awards/index.php?catld=-1&year=2015&view=View Last accessed March 2016
7 Canonica G et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015; 28(5): 309-19.
8 Chrystyn H et al. Int J Pharm, 2015; 491: 268-76.
9 HSCIC England, Wales NHS, HSCNI Northern Ireland, September 2013 to August 2014. ISD Scotland, July 2013 to June 2014
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.